CanSino begun researching mRNA technology in 2018 and has built a facility in Shanghai that can produce up to 200 million doses a year, giving it the capacity to provide similar services to other companies, CanSino's CEO and co-founder Xuefeng Yu told a news agency in an interview.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/8kq4UPE
Home »
Information and Updates: ET HealthWorld : ETHealthworld.com
,
Top Health News | Latest Healthcare Sector & Healthcare Industry news
» China's CanSino seeks more vaccine contracts after AstraZenca deal
https://ift.tt/hlAPSzQ
No comments:
Post a Comment